China blocks completed vertical pharma deal in rare post merger move
China's antitrust regulator has ordered Wuhan Yongtong Pharmaceutical to unwind its 2018 acquisition of Shandong Beida Gaoke Huatai Pharmaceutical, marking an unusual retrospective intervention against a completed merger. The State Administration for...To view the full article, register now.
Already a subscriber? Click here to view full article